Celgene Corporation / Forma Therapeutics Holdings LLC
2013 · Co-Development · $200M · Complete
Announcement Sentiment
92
Strongly positive
Celgene-Forma initial collaboration to discover/develop small molecules targeting protein homeostasis; up to $200M in research and early development funding; Forma led through Phase 1, Celgene took over post.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedApr 25, 2013
ClosedApr 25, 2013
Deal value$200M
Deal typeCo-Development
Therapeutic areaOncology
IndicationsOncology
Key assetsMulti-target protein homeostasis / epigenetics platform
MechanismSmall molecules targeting protein homeostasis pathways